Compare Equitable Holdings Inc. Common Stock (EQH) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equitable Holdings Inc. Common Stock vs Gilead Sciences, Inc. — how do they compare? Equitable Holdings Inc. Common Stock trades at $52.13 (market cap $14.42B), while Gilead Sciences, Inc. trades at $159.21 (market cap $190.38B). The key difference: Gilead Sciences, Inc. is far larger — about 13.2× Equitable Holdings Inc. Common Stock's market cap, and Equitable Holdings Inc. Common Stock pays the higher dividend (2.16%). Which is the better fit depends on your goals — on Pluang, investors hold Equitable Holdings Inc. Common Stock for 0 Days and Gilead Sciences, Inc. for 112 Days on average.
| EQH | GILD | |
|---|---|---|
Market Cap | $14.42B | $190.38B |
Volume | 2,107,298 | 5,758,183 |
Sector | Financials | Health |
52-Week High | $54.50 | $155.80 |
52-Week Low | $35.34 | $117.85 |
Typical Hold Time | 0 Days | 112 Days |
Enterprise Value | $5.48B | $213.45B |
Dividend Yield | 2.16% | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.
EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.
Gilead Sciences (GILD) trades at $147.92, down 1.67% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $153.13. Recent earnings beat expectations in three consecutive quarters, though Q3 2026 results are pending. The company maintains strong operating cash flow of $10.02B in 2025 and has expanded HIV prevention access through a new PAHO partnership in Latin America.
Investment outlook remains positive with 67% analyst buy ratings and potential upside to price targets, though risks include negative net income margin (-10.64%) projected for 2026 and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, but investors should monitor earnings sustainability and pipeline developments in oncology and HIV therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equitable Holdings Inc. Common Stock
Equitable Holdings, Inc. is a financial services holding company operating through Equitable, AllianceBernstein, and Equitable Advisors. It provides retirement and protection products, asset and wealth management services, and financial planning through a network of registered financial professionals.
Read more on EQH →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
